Brain‐targeted co‐delivery of β‐amyloid converting enzyme 1 shRNA and epigallocatechin‐3‐gallate by multifunctional nanocarriers for Alzheimer's disease treatment
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Progressive memory loss and cognitive dysfunction are hallmark clinical features of Alzheimer's disease (AD). As a possible treatment for AD, we developed an epigallocatechin‐3‐gallate (EGCG) and β‐site amyloid precursor protein (APP) cleaving enzyme 1 antisense (BACE1‐AS) shRNA‐encoded plasmid. The plasmid was loaded on to RVG29 peptide‐targeted multifunctional nanoparticles (NPs) (REGS‐PN). The polymeric NPs were characterized by flow cytometry, biocompatibility assay, pharmacokinetic analysis, Western blot analysis, and the Morris water maze (MWM) test. The differences in plasma and brain NP accumulation following intravenous administration showed a significantly longer circulation time for EGS‐PN and REGS‐PN in the blood stream. In contrast, free EGCG was rapidly eliminated from the circulation. REGS‐PM successfully travelled through the blood–brain barrier and was present at a higher concentration in the brain compared with both non‐targeted NPs and free EGCG. REGS‐PN administration to APPswe/PS1dE9 double transgenic mice (APP/PS1 mice) resulted in downregulation of the key enzyme in amyloid‐β formation (BACE1) and amyloid beta, indicating synergistic therapeutic activity. The MWM test revealed that simultaneous delivery of a therapeutic gene and EGCG (REGS‐PN) remarkably improved the spatial learning and memory capabilities of APP/PS1 mice as well as wild type mice compared with the free EGCG‐treated group. With these results, we propose that co‐delivery of a therapeutic gene (shRNA) and EGCG in a multifunctional nanocarrier could achieve higher therapeutic concentrations in the brain and could be an excellent strategy for AD treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00346 · Cited by 3,070
Faghihi, M. A., Modarresi, F., Khalil, A. M., Wood, D. E., Sahagan, B. G., Morgan, T. E., Finch, C. E., St. Laurent III, G., Kenny, P. J., & Wahlestedt, C. (2008) · Nature Medicine · doi:10.1038/nm1784 · Cited by 1,416 · cited 2×
“This suggests that REGS-PM could potentially improve cognitive function and increase memory and learning functions.(12,29)”
BackgroundMethodBillings, L. M., Oddo, S., Green, K. N., McGaugh, J. L., & LaFerla, F. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.040 · Cited by 1,294
Laird, F. M., Cai, H., Savonenko, A. V., Farah, M. H., He, K., Melnikova, T., Wen, H., Chiang, H.-C., Xu, G., Koliatsos, V. E., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2766-05.2005 · Cited by 521
Kandalepas, P. C., Sadleir, K. R., Eimer, W. A., Zhao, J., Nicholson, D. A., & Vassar, R. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1152-3 · Cited by 240
Learning and Memory in Transgenic Mice Modeling Alzheimer's Disease
Ashe, K. H. (2001) · Learning & Memory · doi:10.1101/lm.43701 · Cited by 224
Protective role of epigallocatechin-3-gallate in health and disease: A perspective
Chowdhury, A., Sarkar, J., Chakraborti, T., Pramanik, P. K., & Chakraborti, S. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.12.013 · Cited by 164 · cited 1×
“One possible method is the use of epigallocatechin-3-gallate (EGCG)— an abundant polyphenol of Camellia sinensis.(14) EGCG is a strong antioxidant and directly acts on free radicals via its two gallocatechol rings.”
MethodBACE overexpression alters the subcellular processing of APP and inhibits Aβ deposition in vivo
Lee, E. B., Zhang, B., Liu, K., Greenbaum, E. A., Doms, R. W., Trojanowski, J. Q., & Lee, V. M.-Y. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200407070 · Cited by 140
Caruso, G., Caraci, F., & Jolivet, R. B. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.004 · Cited by 110 · cited 1×
“The pathological features of Aβ include a loss of neurons and neuroinflammation.(6) Therefore, any strategies that focus on the delay or inhibition of Aβ plaque formation prevent symptoms of AD.”
Background
Cited by
Rahman, M. H., Bajgai, J., Fadriquela, A., Sharma, S., Trinh, T. T., Akter, R., Jeong, Y. J., Goh, S. H., Kim, C.-S., & Lee, K.-J. (2021) · Molecules · doi:10.3390/molecules26175327 · Cited by 182
New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease
Zhang, F., Zhong, R.-J., Cheng, C., Li, S., & Le, W.-D. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00565-5 · Cited by 105
Muolokwu, C. E., Chaulagain, B., Gothwal, A., Mahanta, A. K., Tagoe, B., Lamsal, B., & Singh, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1405423 · Cited by 42
Metadata
- Authors
- Lv, L., Yang, F., Li, H., & Yuan, J.
- Venue
- IUBMB Life
- Publisher
- Wiley
- Published
- 2020-07-15
- Volume
- 72
- Issue
- 8
- Pages
- 1819-1829
- ISSN
- 1521-6543 (ISSN-L)
- 1521-6551
- OpenAlex
- W3042653455
- Cited by
- 39
- References
- 9
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.